Role of oxylipins generated from dietary PUFAs in the modulation of endothelial cell function. (September 2020)

• Record Type: Journal Article
• Authors: Du, Youjia; Taylor, Carla G.; Aukema, Harold M.; Zahradka, Peter
• Is Part Of: Prostaglandins, leukotrienes, and essential fatty acids. Volume 160(2020)
• Publication Date: 2020-09
• Subjects: Oxylipin -- dietary polyunsaturated fatty acid -- endothelial cell -- endothelial cell function; AAN aristolochic acid nephropathy -- ACE angiotensin-converting enzyme -- Ach acetylcholine -- AdA adrenic acid -- AIx augmentation index -- AJ adherens junction -- Akt protein kinase B -- Alk anaplastic lymphoma kinase -- ALX/FPR2 G-protein coupled formyl peptide receptor 2 -- AMPK 5′ adenosine monophosphate-activated protein kinase -- AP-1 activating protein-1 -- AT-III anti-thrombin III -- ATF-2 activating transcription factor-2 -- BAEC bovine aortic endothelial cell -- Bcl-2 B-cell lymphoma 2 -- BEC bovine endothelial cell -- BLT leukotriene B4 receptor -- BPAEC bovine pulmonary arterial endothelial cell -- c-IAP1 cellular inhibitor of apoptosis protein-1 -- CAM cell adhesion molecule -- CEC circulating endothelial cell -- cGMP cyclic guanosine monophosphate -- COX cyclooxygenase -- CREB cAMP response element binding protein -- CYP450 cytochrome P450 -- CysLT2R cysteinyl leukotriene receptor 2 -- DAG diacylglycerol -- E2F-1 E2F transcription factor-1 -- EC endothelial cell -- EDHF endothelium-derived hyperpolarizing factor -- EFK eukaryotic elongation factor kinase -- Egr-1 early growth response protein-1 -- ELAM-1 endothelial-leukocyte adhesion molecule-1 -- EMP endothelial microparticle -- eNOS endothelial nitric oxide synthase -- EP prostaglandin E receptor -- Epac exchange protein directly activated by cAMP -- EPC endothelial progenitor cell -- EpETrE epoxy-eicosatrienoic acid -- ERK extracellular signal-regulated kinase -- Ex eoxin -- FA fatty acid -- FGF fibroblast growth factor -- FGFR fibroblast growth factor receptor -- Flt-1 Fms related tyrosine kinase-1 -- FMD flow mediated dilation -- FP receptor prostaglandin F receptor -- Frk Fyn-related kinase -- GPR32 G protein-coupled receptor 32 -- GSH glutathione -- GTPase guanosine triphosphatase -- HDMEC human dermal microvascular endothelial cell -- HDoHE hydroxy-docosahexaenoic acid -- HEPE hydroxy-eicosapentaenoic acid -- HETE hydroxy-eicosatetraenoic acid -- HETrE hydroxy-eicosatrienoic acid -- HGF hepatocyte growth factor -- HIF-1α hypoxia-inducible factor-1α -- HMVEC human microvascular endothelial cell -- HODE hydroxy-octadecadienoic acid -- HpETE hydroperoxy-eicosatetraenoic acid -- HpODE hydroperoxy-octadecadienoic acid -- HREC human retinal endothelial cell -- HSP heat shock protein -- HUVEC human umbilical vein endothelial cell -- ICAM intercellular adhesion molecule -- IFN-γ interferon-γ -- IKK IκB kinase -- IL-1 interleukin-1 -- IL-8 interleukin-8 -- IL interleukin -- iNOS inducible nitric oxide synthase -- IP prostacyclin receptor -- IP3 inositol triphosphate -- IV intravenous -- IκB-α inhibitor of kappa B-α -- IκB inhibitor of NF-κB -- JAK/STAT Janus kinase/signal transducers and activators of transcription -- Jam A junction adhesion molecule A -- JNK c-Jun N-terminal kinase -- LOX lipoxygenase -- LPS lipopolysaccharide -- Lt leukotriene -- Lx lipoxin -- MAPK mitogen activated protein kinase -- MaR maresin -- MCP-1 monocyte chemoattractant protein-1 -- MEK-1 mitogen-activated protein kinase kinase-1 -- MMP matrix metalloproteinase -- mTORC mammalian target of rapamycin complex -- NADPH oxidase nicotinamide adenine dinucleotide phosphate-oxidase -- NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells -- NO nitric oxide -- NOX NADPH oxidase -- Nrf2 nuclear factor-like-2 factor -- ox-LDL oxidized low density lipoprotein -- oxo-ETE oxo-eicosatetraenoic acid -- p-eNOS phosphorylated endothelial nitric oxide synthase -- p53 cellular tumor antigen p53 -- PA plasminogen activator -- PAD peripheral artery disease -- PAF platelet activating factor -- PAI plasminogen activator inhibitor -- PAK serine/threonine-protein kinase -- PECAM-1 platelet endothelial cell adhesion molecule-1 -- PG prostaglandin -- PGC-1α peroxisome proliferator-activated receptor-γ coactivator-1α -- PGI prostacyclin -- PI3K phosphoinositide 3-kinase -- PKA protein kinase A -- PKC protein kinase C -- PLC phospholipase C -- PMA phorbol 12-myristate 13-acetate -- PMN polymorphonuclear neutrophil -- PP2A protein phosphatase 2 -- PPAR-γ peroxisome proliferator-activated receptor-γ -- PUFA polyunsaturated fatty acid -- PWA pulse wave analysis -- PWV pulse wave velocity -- Rap/Rac1 Ras-related protein 1/Ras-related C3 botulinum toxin substrate 1 -- RBC red blood cell -- Rho Rho protein -- ROR-α retinoic acid receptor-related orphan receptor-α -- ROS reactive oxygen species -- PROX1 prospero homebox protein 1 -- RvD resolvin -- S6K1 ribosomal protein S6 kinase beta-1 -- SHP2 Src-homology 2 domain-containing phosphatase 2 -- sICAM-1 soluble intercellular adhesion molecule-1 -- Smad3 mothers against decapentaplegic homolog 3 -- SOX18 SRY-related HMG-box 18 -- Src proto-oncogene tyrosine-protein kinase -- sVCAM-1 soluble vascular cell adhesion molecule-1 -- TxA2 thromboxane A2 -- TBXA2R thromboxane A2 receptor -- TEER transendothelial electrical resistance -- TGFβ transforming growth factor-β -- Tiam1 T-lymphoma invasion and metastasis-inducing protein 1 -- TJ tight junction -- TNF-α tumor necrosis factor-α -- TP thromboxane receptor -- t-PA tissue type plasminogen activator -- tPAI tissue type plasminogen activator inhibitor -- Tx thromboxane -- VCAM vascular cell adhesion molecule -- VEGF vascular endothelial growth factor -- VEGFR vascular endothelial growth factor receptor -- VSMC vascular smooth muscle cell -- vWF von Willebrand Factor -- XIAP X-linked inhibitor of apoptosis protein -- XO xanthine oxidase -- ZO zonula occluden; Lipids -- Periodicals; Unsaturated fatty acids -- Periodicals; Prostaglandins -- Periodicals; Leukotrienes -- Periodicals; Fatty Acids, Unsaturated -- Periodicals; Acides gras insaturés -- Périodiques; Prostaglandines -- Périodiques; Leucotriènes -- Périodiques; Lipides -- Périodiques; 612.01577
• DOI: 10.1016/j.plefa.2020.102160
• Languages: English
• ISSNs: 0952-3278

Abstract

Highlights: Summary of effects of oxylipins on endothelial cells in vitro, ex vivo & in vivo. Describes key mechanisms by which oxylipins modulate endothelial cell function. DHA-derived oxylipins show beneficial effects on endothelial cells. Studies on ALA-derived oxylipins and endothelial cells are lacking. Abstract: Oxylipins, which are circulating bioactive lipids generated from polyunsaturated fatty acids (PUFAs) by cyclooxygenase, lipooxygenase and cytochrome P450 enzymes, have diverse effects on endothelial cells. Although studies of the effects of oxylipins on endothelial cell function are accumulating, a review that provides a comprehensive compilation of current knowledge and recent advances in the context of vascular homeostasis is lacking. This is the first compilation of the various in vitro, ex vivo and in vivo reports to examine the effects and potential mechanisms of action of oxylipins on endothelial cells. The aggregate data indicate docosahexaenoic acid-derived oxylipins consistently show beneficial effects related to key endothelial cell functions, whereas oxylipins derived from other PUFAs exhibit both positive and negative effects. Furthermore, information is lacking for certain oxylipin classes, such as those derived from α-linolenic acid, which suggests additional studies are required to achieve a full understanding of how oxylipins affect endothelial cells.